• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Effect of statin use on clinical outcomes in ischemic stroke patients with atrial fibrillation
The objective of this study was to clarify whether statin therapy can influence the prognosis in recent ischemic stroke patients with atrial fibrillation. We identified ischemic stroke patients with atrial fibrillation between 2001 and 2011 from Taiwan National Health Insurance Database. Patients not treated with statins during the first 90 days after the index stroke were matched to patients treated with statins in the first 90 days in a 2:1 ratio on the basis of age, sex, hypertension, diabetes mellitus, ischemic heart disease, heart failure, estimated National Institutes of Health Stroke Scale, use of anticoagulant, an...
Source: Medicine - February 1, 2017 Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research

Compliance with recommendations in secondary prevention of stroke in primary care.
CONCLUSIONS: The implementation of clinical guidelines recommendations for stroke prevention in primary care must be improved, especially among younger population. Organizational changes and more active involvement by professionals and strategies against therapeutic inertia must be taken. PMID: 28395917 [PubMed - as supplied by publisher]
Source: Atencion Primaria - April 7, 2017 Category: Primary Care Authors: Tamayo-Ojeda C, Parellada-Esquius N, Salvador-González B, Oriol-Torón PÁ, Rodríguez-Garrido MD, Muñoz-Segura D, en representación del grupo de investigación del proyecto «Adherencia a las recomendaciones de las guías de práctica clínica en la p Tags: Aten Primaria Source Type: research

Residual Ischemic Risk and Its Determinants in Patients With Previous Myocardial Infarction and Without Prior Stroke or TIA: Insights From the REACH Registry
ConclusionsIn this study, residual ischemic risk after MI accrued progressively up to 4 years of follow‐up, emphasizing the value of intensive secondary prevention strategies to minimize residual risk.
Source: Clinical Cardiology - July 31, 2016 Category: Cardiology Authors: J érémie Abtan, Deepak L. Bhatt, Yedid Elbez, Emmanuel Sorbets, Kim Eagle, Yasuo Ikeda, David Wu, Mary E. Hanson, Hakima Hannachi, Puneet K. Singhal, Philippe Gabriel Steg, Gregory Ducrocq, Tags: Clinical Investigations Source Type: research

Long-Term Use of Statins Lowering the Risk of Rehospitalization Caused by Ischemic Stroke Among Middle-Aged Hyperlipidemic Patients: A Population-Based Study
Conclusion: Statins were associated with long-term secondary prevention of reHospIS for hyperlipidemic patients. Rosuvastatin seemed to have the best protective effects. On the other hand, Bezafibrate appears to be beneficial for hyperlipidemic patients developing diabetes. Further research into the combination treatment of statin and nonstatin lipid-lowering medicines in hyperlipidemic patients developing diabetes is warranted.
Source: Frontiers in Pharmacology - October 18, 2021 Category: Drugs & Pharmacology Source Type: research

Could exercise be as effective as medication?
Conclusion The researchers found that there are very few trials that directly compare exercise with drug therapy for any condition. They were only able to find enough trials to be able to analyse results for four major conditions. They found that exercise reduced death rates for people after a stroke (although this analysis has limitations and should be interpreted cautiously), and that drug therapy with diuretics improved death rates for people with heart failure. They did not find any difference between exercise and drug therapy for death rates after a heart attack or in people with pre-diabetes. There were several limit...
Source: NHS News Feed - October 2, 2013 Category: Consumer Health News Tags: Lifestyle/exercise Heart/lungs Medication Source Type: news

Adverse Effects of Statins
In Reply Dr Goldstein questions the relationship between cholesterol levels, statins, and hemorrhagic stroke. Evidence for the association between low –total serum cholesterol levels, which is mostly LDL-C, and an increased risk of hemorrhagic stroke has been available since at least the late 1980s. A meta-analysis of 23 studies including 1.4 million participants and 7960 hemorrhagic strokes found that the RR of hemorrhagic stroke was 38% higher (95% CI, 8%-59%) in patients with the highest vs lowest LDL-C values. The Cholesterol Treatment Trialists’ Collaboration meta-analysis of 26 trials showed a nonsignificant incr...
Source: JAMA - March 14, 2017 Category: Journals (General) Source Type: research

Moderate drinking may reduce heart disease risk
Conclusion This study paints a more complicated picture than the "Pint a day keeps the doctor away" story proffered by The Sun. It seems to confirm the findings of other studies, which have shown that non-drinkers tend to have a higher risk of cardiovascular diseases than people who drink moderately. It suggests that some cardiovascular diseases (mainly those directly affecting the heart) seem to have a stronger link to a possible protective effect from alcohol than other vascular diseases, such as mini-strokes and bleeding in the brain. However, this can't be concluded with certainty due to the study design. We ...
Source: NHS News Feed - March 23, 2017 Category: Consumer Health News Tags: Heart/lungs Food/diet Lifestyle/exercise Source Type: news

EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
Abstract During the last decade, the armamentarium for glucose-lowering drugs has increased enormously by the development of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT2 inhibitors, allowing individualization of antidiabetic therapy for patients with type 2 diabetes (T2DM). Some combinations can now be used without an increased risk for severe hypoglycemia and weight gain. Following a request of the US Food and Drug Administration, many large cardiovascular (CV) outcome studies have been performed in patients with longstanding disease and established CV disease. In the majority of CV outcome studies, CV ris...
Source: Clinical Therapeutics - May 18, 2016 Category: Drugs & Pharmacology Authors: Schernthaner G, Schernthaner-Reiter MH, Schernthaner GH Tags: Clin Ther Source Type: research

Association between low-density lipoprotein cholesterol and cardiovascular mortality in statin non-users: a prospective cohort study in 14.9 million Korean adults
ConclusionLDL-C had U-curve associations for CVD mortality. The associations and optimal ranges differed across CVD subtypes. Women and older adults had weaker positive associations than men and younger adults. Positive associations with ischaemic heart disease and ischaemic stroke were maintained in adults aged 75 –84 years.
Source: International Journal of Epidemiology - February 26, 2022 Category: Epidemiology Source Type: research

Real world adherence to oral anticoagulant in non-valvular atrial fibrillation patients in China.
CONCLUSION: Oral anticoagulation was significantly underused in NVAF patients in China. Age, sex, concurrent drug usage and disease history were associated factors. Improving warfarin adherence was promising to reduce ischemic stroke risk of NVAF patients. PMID: 29022745 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - October 13, 2017 Category: Research Tags: Curr Med Res Opin Source Type: research

Multi-proteomic approach to predict specific cardiovascular events in patients with diabetes and myocardial infarction: findings from the EXAMINE trial
ConclusionsThe addition of multi-proteomic biomarkers to a clinical model in this population with diabetes and a recent MI allowed a better risk prediction and event reclassification, potentially helping for better risk assessment and targeted treatment decisions.Graphic abstractT2D type 2 diabetes,MI myocardial infarction,CV cardiovascular,HFH heart failure hospitalization,Δ delta,cNRI continuous net reclassification index,BNP brain natriuretic peptide,TRAILR2 trail receptor 2 (or death receptor 5),Gal-9 galectin-9,FGF23 fibroblast growth factor 23.
Source: Clinical Research in Cardiology - August 12, 2020 Category: Cardiology Source Type: research

Statins for acute coronary syndrome.
CONCLUSIONS: Based on moderate quality evidence, due to concerns about risk of bias and imprecision, initiation of statin therapy within 14 days following ACS does not reduce death, myocardial infarction, or stroke up to four months, but reduces the occurrence of unstable angina at four months following ACS. Serious side effects were rare. PMID: 25178118 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - September 1, 2014 Category: Journals (General) Authors: Vale N, Nordmann AJ, Schwartz GG, de Lemos J, Colivicchi F, den Hartog F, Ostadal P, Macin SM, Liem AH, Mills EJ, Bhatnagar N, Bucher HC, Briel M Tags: Cochrane Database Syst Rev Source Type: research

PCSK9 inhibitors: a major advance in cholesterol-lowering drug therapy
Every so often a medical advance comes along that rewrites the script for treating a disease or condition. After today’s announcements of impressive results of a new type of cholesterol-lowering drug, that scenario just might happen in the next few years. The new drugs, called PCSK9 inhibitors, are monoclonal antibodies. They target and inactivate a specific protein in the liver. Knocking out this protein, called proprotein convertase subtilisin kexin 9, dramatically reduces the amount of harmful LDL cholesterol circulating in the bloodstream. Lower LDL translates into healthier arteries and fewer heart attacks, stro...
Source: New Harvard Health Information - March 15, 2015 Category: Consumer Health News Authors: Gregory Curfman, MD Tags: Drugs and Supplements Heart Health Medical Research alirocumab cholesterol evolocumab PCSK9 inhibitors Source Type: news

High-intensity statin therapy in patients with chronic kidney disease: a systematic review and meta-analysis
Conclusions High-intensity statin therapy could effectively reduce the risk of stroke in patients with CKD. However, its effects on all-cause mortality, myocardial infarction, heart failure and renal protection remain unclear. Moreover, it is hard to draw conclusions on the safety assessment of intensive statin treatment in this particular population. More studies are needed to credibly evaluate the effects of high-intensity statin therapy in patients with CKD.
Source: BMJ Open - May 15, 2015 Category: Journals (General) Authors: Yan, Y.-L., Qiu, B., Wang, J., Deng, S.-B., Wu, L., Jing, X.-D., Du, J.-L., Liu, Y.-J., She, Q. Tags: Open access, Cardiovascular medicine, Pharmacology and therapeutics Research Source Type: research

Drugs, money and your heart
I was really excited to see a recent headline that said heart doctors should discuss herbal medicines with their patients. The recommendation came from a study in the Journal of the American College of Cardiology.1 I thought this was a real breakthrough. I thought it meant cardiologists had finally seen the light… Boy, was I wrong… The article said doctors should learn about herbal medicines so they could STOP their patients from using them. You see, supplement use is at an all-time high. About 70% of Americans take them. That’s a lot of people. And Big Pharma would love to capture that market. So they have a re...
Source: Al Sears, MD Natural Remedies - October 5, 2017 Category: Complementary Medicine Authors: Cathy Card Tags: Anti-Aging Source Type: news

Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13